Published in Bone on October 24, 2006
Advanced glycation endproducts induce podocyte apoptosis by activation of the FOXO4 transcription factor. Kidney Int (2007) 1.42
Glucocorticoid induces apoptosis of osteoblast cells through the activation of glycogen synthase kinase 3beta. J Bone Miner Metab (2008) 1.28
Diabetic complications and dysregulated innate immunity. Front Biosci (2008) 1.28
Periodontal disease: the influence of metabolic syndrome. Nutr Metab (Lond) (2012) 1.22
Activation of the acquired immune response reduces coupled bone formation in response to a periodontal pathogen. J Immunol (2008) 1.11
Transamidation by transglutaminase 2 transforms S100A11 calgranulin into a procatabolic cytokine for chondrocytes. J Immunol (2008) 1.08
The effect of the microscopic and nanoscale structure on bone fragility. Osteoporos Int (2008) 1.07
In situ accumulation of advanced glycation endproducts (AGEs) in bone matrix and its correlation with osteoclastic bone resorption. Bone (2011) 1.04
Loss of RAGE defense: a cause of Charcot neuroarthropathy? Diabetes Care (2011) 1.02
Advanced glycation end products induce human corneal epithelial cells apoptosis through generation of reactive oxygen species and activation of JNK and p38 MAPK pathways. PLoS One (2013) 0.97
Diabetes, biochemical markers of bone turnover, diabetes control, and bone. Front Endocrinol (Lausanne) (2013) 0.94
Osteoporosis and type 2 diabetes mellitus: what do we know, and what we can do? Patient Prefer Adherence (2012) 0.93
Inflammation as death or life signal in diabetic fracture healing. Inflamm Res (2010) 0.93
FOXO1 differentially regulates both normal and diabetic wound healing. J Cell Biol (2015) 0.89
Precursor of advanced glycation end products mediates ER-stress-induced caspase-3 activation of human dermal fibroblasts through NAD(P)H oxidase 4. PLoS One (2010) 0.89
High serum pentosidine but not esRAGE is associated with prevalent fractures in type 1 diabetes independent of bone mineral density and glycaemic control. Osteoporos Int (2014) 0.89
Collagen advanced glycation inhibits its Discoidin Domain Receptor 2 (DDR2)-mediated induction of lysyl oxidase in osteoblasts. Bone (2013) 0.89
Diabetes mellitus related bone metabolism and periodontal disease. Int J Oral Sci (2015) 0.88
Association of hand or knee osteoarthritis with diabetes mellitus in a population of Hispanics from Puerto Rico. J Clin Rheumatol (2013) 0.88
Immunology of Osteoporosis: A Mini-Review. Gerontology (2015) 0.88
Diabetes and Its Effect on Bone and Fracture Healing. Curr Osteoporos Rep (2015) 0.86
MiR-378 overexpression attenuates high glucose-suppressed osteogenic differentiation through targeting CASP3 and activating PI3K/Akt signaling pathway. Int J Clin Exp Pathol (2014) 0.85
Biochemical markers of bone turnover in diabetes patients--a meta-analysis, and a methodological study on the effects of glucose on bone markers. Osteoporos Int (2014) 0.85
The question is, my dear watson, why did the dog not bark?: the joslin 50-year medalist study. Diabetes Care (2011) 0.84
Resistance Training in Type II Diabetes Mellitus: Impact on Areas of Metabolic Dysfunction in Skeletal Muscle and Potential Impact on Bone. J Nutr Metab (2012) 0.84
Advanced glycation end products induce cell cycle arrest and proinflammatory changes in osteoarthritic fibroblast-like synovial cells. Arthritis Res Ther (2009) 0.84
RAGE and its ligands in bone metabolism. Front Biosci (Schol Ed) (2011) 0.83
Anti-inflammatory Actions of Adjunctive Tetracyclines and Other Agents in Periodontitis and Associated Comorbidities. Open Dent J (2014) 0.83
The pathogenesis of Charcot neuroarthropathy: current concepts. Diabet Foot Ankle (2012) 0.83
The effects of raloxifene on bone turnover markers and bone mineral density in women on maintenance hemodialysis. Clin Exp Nephrol (2010) 0.83
Effects of raloxifene on lipid and bone metabolism in postmenopausal women with type 2 diabetes. J Bone Miner Metab (2012) 0.82
Type II collagen levels correlate with mineralization by articular cartilage vesicles. Arthritis Rheum (2009) 0.81
Advanced glycation end products (AGEs) and their receptor (RAGE) induce apoptosis of periodontal ligament fibroblasts. Braz J Med Biol Res (2014) 0.79
Childhood obesity, bone development, and cardiometabolic risk factors. Mol Cell Endocrinol (2015) 0.79
Advanced glycation end products play adverse proinflammatory activities in osteoporosis. Mediators Inflamm (2014) 0.79
The cumulative incidence of and risk factors for latent beaking in patients with autoimmune diseases taking long-term glucocorticoids and bisphosphonates. Osteoporos Int (2015) 0.78
Pathophysiological role of enhanced bone marrow adipogenesis in diabetic complications. Adipocyte (2014) 0.78
Evaluation of bone mineral density among type 2 diabetes mellitus patients in South Karnataka. J Nat Sci Biol Med (2017) 0.78
Oxidative Stress and Dietary Fat Type in Relation to Periodontal Disease. Antioxidants (Basel) (2015) 0.77
Effect of advanced glycosylation end products on apoptosis in human adipose tissue-derived stem cells in vitro. Cell Biosci (2015) 0.77
Augmented LPS responsiveness in type 1 diabetes-derived osteoclasts. J Cell Physiol (2013) 0.77
Cytotoxicity of advanced glycation endproducts in human micro- and astroglial cell lines depends on the degree of protein glycation. J Neural Transm (Vienna) (2008) 0.76
Biological Effects Induced by Specific Advanced Glycation End Products in the Reconstructed Skin Model of Aging. Biores Open Access (2015) 0.76
Influence of high glucose and advanced glycation end-products (ages) levels in human osteoblast-like cells gene expression. BMC Musculoskelet Disord (2016) 0.75
Effect of targeted delivery of bone morphogenetic protein-2 on bone formation in type 1 diabetes. Int J Oral Maxillofac Implants (2015) 0.75
The complex relationship between bone remodeling and the physical and material properties of bone. Osteoporos Int (2014) 0.75
Bone mechanical properties and changes with osteoporosis. Injury (2016) 0.75
Diabetes Stimulates Osteoclastogenesis by Acidosis-Induced Activation of Transient Receptor Potential Cation Channels. Sci Rep (2016) 0.75
Advanced Glycation End Products, Diabetes, and Bone Strength. Curr Osteoporos Rep (2016) 0.75
Evaluation of circulating sRAGE in osteoporosis according to BMI, adipokines and fracture risk: a pilot observational study. Immun Ageing (2017) 0.75
IP6K1 Reduces Mesenchymal Stem/Stromal Cell Fitness and Potentiates High Fat Diet-Induced Skeletal Involution. Stem Cells (2017) 0.75
High fat diet attenuates hyperglycemia, body composition changes, and bone loss in male streptozotocin-induced type 1 diabetic mice. J Cell Physiol (2017) 0.75
Influence of bread crust-derived Maillard reaction products on phosphorus balance in rats. Eur J Nutr (2011) 0.75
Visit-to-visit variation of fasting plasma glucose is a predictor of hip fracture in older persons with type 2 diabetes: the Taiwan Diabetes Study. Osteoporos Int (2016) 0.75
Thioredoxin plays a key role in retinal neuropathy prior to endothelial damage in diabetic mice. Oncotarget (2017) 0.75
Cortical bone laminar analysis reveals increased midcortical and periosteal porosity in type 2 diabetic postmenopausal women with history of fragility fractures compared to fracture-free diabetics. Osteoporos Int (2016) 0.75
Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science (2002) 14.50
NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science (1998) 11.70
Determination of free amino groups in proteins by trinitrobenzenesulfonic acid. Anal Biochem (1966) 7.11
Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest (1998) 5.03
Advanced glycation end-products: a review. Diabetologia (2001) 4.59
p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov (2003) 4.58
N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem (1999) 3.72
Role of JNK activation in apoptosis: a double-edged sword. Cell Res (2005) 3.48
Diabetes and advanced glycation endproducts. J Intern Med (2002) 3.38
The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta (2000) 3.33
Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology (2003) 2.84
Mineralized bone nodules formed in vitro from enzymatically released rat calvaria cell populations. Calcif Tissue Int (1986) 2.71
Pathogenesis of bone fragility in women and men. Lancet (2002) 2.64
Tumor necrosis factor: an apoptosis JuNKie? Cell (2004) 2.64
Accumulation of Maillard reaction products in skin collagen in diabetes and aging. J Clin Invest (1993) 2.40
N epsilon-(carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins. Biochemistry (1995) 2.19
Osteoblast-derived PTHrP is a potent endogenous bone anabolic agent that modifies the therapeutic efficacy of administered PTH 1-34. J Clin Invest (2005) 1.88
Glycation of collagen: the basis of its central role in the late complications of ageing and diabetes. Int J Biochem Cell Biol (1996) 1.82
Blockade of RAGE suppresses periodontitis-associated bone loss in diabetic mice. J Clin Invest (2000) 1.82
Identification of the critical features of a small peptide inhibitor of JNK activity. J Biol Chem (2002) 1.80
Diabetes Mellitus: Does it Affect Bone? Calcif Tissue Int (2003) 1.77
FOXO1 functions as a master switch that regulates gene expression necessary for tumor necrosis factor-induced fibroblast apoptosis. J Biol Chem (2005) 1.63
Specific activation of the p38 mitogen-activated protein kinase signaling pathway and induction of neurite outgrowth in PC12 cells by bone morphogenetic protein-2. J Biol Chem (1999) 1.36
A role for advanced glycation end products in diminished bone healing in type 1 diabetes. Diabetes (2003) 1.34
Advanced glycation end-products attenuate human mesenchymal stem cells and prevent cognate differentiation into adipose tissue, cartilage, and bone. J Bone Miner Res (2005) 1.29
Tumor necrosis factor-alpha mediates diabetes-enhanced apoptosis of matrix-producing cells and impairs diabetic healing. Am J Pathol (2006) 1.25
Diabetes causes decreased osteoclastogenesis, reduced bone formation, and enhanced apoptosis of osteoblastic cells in bacteria stimulated bone loss. Endocrinology (2003) 1.25
Apoptosis is increased in a model of diabetes-impaired wound healing in genetically diabetic mice. Int J Biochem Cell Biol (1997) 1.21
Advanced glycation end products enhance expression of pro-apoptotic genes and stimulate fibroblast apoptosis through cytoplasmic and mitochondrial pathways. J Biol Chem (2004) 1.18
Skeletal involvement in patients with diabetes mellitus. Diabetes Metab Res Rev (2004) 1.16
Advanced glycation end-products pentosidine and N epsilon-carboxymethyllysine are elevated in serum of patients with osteoporosis. Rheumatology (Oxford) (2003) 1.16
Diabetes alters the response to bacteria by enhancing fibroblast apoptosis. Endocrinology (2004) 1.12
Alterations of cartilage and collagen expression during fracture healing in experimental diabetes. Connect Tissue Res (2000) 1.09
Possible participation of advanced glycation end products in the pathogenesis of osteoporosis in diabetic patients. Med Hypotheses (2005) 1.08
Diabetes enhances mRNA levels of proapoptotic genes and caspase activity, which contribute to impaired healing. Diabetes (2006) 1.08
Glycation end-product cross-link breaker reduces collagen and improves cardiac function in aging diabetic heart. Am J Physiol Heart Circ Physiol (2003) 1.08
Histological evidence of the altered distribution of osteocytes and bone matrix synthesis in klotho-deficient mice. Arch Histol Cytol (2005) 1.03
Non-enzymatic glycosylation of a type I collagen matrix: effects on osteoblastic development and oxidative stress. BMC Cell Biol (2001) 1.01
Evaluation of bone turnover in postmenopausal patients with type 2 diabetes mellitus using biochemical markers and bone mineral density measurements. Gynecol Endocrinol (2003) 1.01
Advanced glycation end product modification of bone proteins and bone remodelling: hypothesis and preliminary immunohistochemical findings. Ann Rheum Dis (2006) 1.00
Bone mineral homeostasis in spontaneously diabetic BB rats. II. Impaired bone turnover and decreased osteocalcin synthesis. Endocrinology (1989) 0.98
Advanced glycation endproducts stimulate interleukin-6 production by human bone-derived cells. J Bone Miner Res (1997) 0.98
The triggering of human peritoneal mesothelial cell apoptosis and oncosis by glucose and glycoxydation products. Nephrol Dial Transplant (2004) 0.98
Methylglyoxal induces apoptosis through activation of p38 mitogen-activated protein kinase in rat mesangial cells. Kidney Int (2003) 0.97
TNF-alpha in vivo stimulates apoptosis in fibroblasts through caspase-8 activation and modulates the expression of pro-apoptotic genes. J Cell Physiol (2004) 0.97
2-ammonio-6-(3-oxidopyridinium-1-yl)hexanoate (OP-lysine) is a newly identified advanced glycation end product in cataractous and aged human lenses. J Biol Chem (2003) 0.95
Role of advanced glycation end products in adynamic bone disease in patients with diabetic nephropathy. Am J Kidney Dis (2001) 0.89
Increased osteoblast apoptosis in apert craniosynostosis: role of protein kinase C and interleukin-1. Am J Pathol (2001) 0.88
Reduced cell replication and induction of apoptosis by advanced glycation end products in rat Schwann cells. Biochem Biophys Res Commun (2004) 0.86
Advanced glycation endproducts and osteoarthritis. Curr Rheumatol Rep (2003) 0.86
Inhibition of matrix-induced bone differentiation by advanced glycation end-products in rats. Diabetologia (1993) 0.82
H-Ras/mitogen-activated protein kinase pathway inhibits integrin-mediated adhesion and induces apoptosis in osteoblasts. J Biol Chem (2002) 0.81
JNK/SAPK is required in nitric oxide-induced apoptosis in osteoblasts. Arch Pharm Res (2003) 0.80
Fracture healing as a post-natal developmental process: molecular, spatial, and temporal aspects of its regulation. J Cell Biochem (2003) 4.34
BMP2 activity, although dispensable for bone formation, is required for the initiation of fracture healing. Nat Genet (2006) 3.79
Relationship between the red cell distribution width and the one-year outcomes in Chinese patients with stable angina pectoris. Intern Med (2012) 3.42
Effect of micro-osteoperforations on the rate of tooth movement. Am J Orthod Dentofacial Orthop (2013) 2.09
A fluorometric assay for detection of lysyl oxidase enzyme activity in biological samples. Anal Biochem (2002) 1.84
Interleukin-1 receptor signaling mediates atherosclerosis associated with bacterial exposure and/or a high-fat diet in a murine apolipoprotein E heterozygote model: pharmacotherapeutic implications. Circulation (2004) 1.82
Cytokine profiling of macrophages exposed to Porphyromonas gingivalis, its lipopolysaccharide, or its FimA protein. Infect Immun (2005) 1.77
Comparison of effects of the bisphosphonate alendronate versus the RANKL inhibitor denosumab on murine fracture healing. J Bone Miner Res (2009) 1.68
Diminished bone formation during diabetic fracture healing is related to the premature resorption of cartilage associated with increased osteoclast activity. J Bone Miner Res (2007) 1.67
FOXO1 functions as a master switch that regulates gene expression necessary for tumor necrosis factor-induced fibroblast apoptosis. J Biol Chem (2005) 1.63
Diabetes-enhanced tumor necrosis factor-alpha production promotes apoptosis and the loss of retinal microvascular cells in type 1 and type 2 models of diabetic retinopathy. Am J Pathol (2008) 1.61
Enhanced chondrogenesis and Wnt signaling in PTH-treated fractures. J Bone Miner Res (2007) 1.59
Qualitative and quantitative differences between bone graft obtained from the medullary canal (with a Reamer/Irrigator/Aspirator) and the iliac crest of the same patient. J Bone Joint Surg Am (2012) 1.50
Three-dimensional reconstruction of fracture callus morphogenesis. J Histochem Cytochem (2006) 1.48
The propeptide domain of lysyl oxidase induces phenotypic reversion of ras-transformed cells. J Biol Chem (2004) 1.47
The association between rheumatoid arthritis and periodontal disease. Arthritis Res Ther (2010) 1.47
The tumor suppressor activity of the lysyl oxidase propeptide reverses the invasive phenotype of Her-2/neu-driven breast cancer. Cancer Res (2007) 1.41
Diabetes interferes with the bone formation by affecting the expression of transcription factors that regulate osteoblast differentiation. Endocrinology (2003) 1.41
The lysyl oxidase pro-peptide attenuates fibronectin-mediated activation of focal adhesion kinase and p130Cas in breast cancer cells. J Biol Chem (2008) 1.41
Diabetes prolongs the inflammatory response to a bacterial stimulus through cytokine dysregulation. J Invest Dermatol (2004) 1.40
Hereditary gingival fibromatosis associated with generalized aggressive periodontitis: a case report. J Periodontol (2004) 1.36
A role for advanced glycation end products in diminished bone healing in type 1 diabetes. Diabetes (2003) 1.34
Repression of BCL2 by the tumor suppressor activity of the lysyl oxidase propeptide inhibits transformed phenotype of lung and pancreatic cancer cells. Cancer Res (2007) 1.31
Mammalian target of rapamycin complex 2 (mTORC2) negatively regulates Toll-like receptor 4-mediated inflammatory response via FoxO1. J Biol Chem (2011) 1.31
Role of forkhead transcription factors in diabetes-induced oxidative stress. Exp Diabetes Res (2012) 1.27
CCN2, connective tissue growth factor, stimulates collagen deposition by gingival fibroblasts via module 3 and alpha6- and beta1 integrins. J Cell Biochem (2006) 1.26
Tumor necrosis factor-alpha mediates diabetes-enhanced apoptosis of matrix-producing cells and impairs diabetic healing. Am J Pathol (2006) 1.25
FOXO1 plays an important role in enhanced microvascular cell apoptosis and microvascular cell loss in type 1 and type 2 diabetic rats. Diabetes (2009) 1.25
Diabetes causes decreased osteoclastogenesis, reduced bone formation, and enhanced apoptosis of osteoblastic cells in bacteria stimulated bone loss. Endocrinology (2003) 1.25
FOXO1 promotes wound healing through the up-regulation of TGF-β1 and prevention of oxidative stress. J Cell Biol (2013) 1.22
High levels of tumor necrosis factor-alpha contribute to accelerated loss of cartilage in diabetic fracture healing. Am J Pathol (2009) 1.20
Advanced glycation end products enhance expression of pro-apoptotic genes and stimulate fibroblast apoptosis through cytoplasmic and mitochondrial pathways. J Biol Chem (2004) 1.18
Advanced glycation end products induce apoptosis in fibroblasts through activation of ROS, MAP kinases, and the FOXO1 transcription factor. Am J Physiol Cell Physiol (2006) 1.16
A loss-of-function polymorphism in the propeptide domain of the LOX gene and breast cancer. Cancer Res (2009) 1.14
Diabetes alters the response to bacteria by enhancing fibroblast apoptosis. Endocrinology (2004) 1.12
A role for lysyl oxidase regulation in the control of normal collagen deposition in differentiating osteoblast cultures. J Cell Physiol (2004) 1.11
Activation of the acquired immune response reduces coupled bone formation in response to a periodontal pathogen. J Immunol (2008) 1.11
TNF-alpha mediates diabetes-enhanced chondrocyte apoptosis during fracture healing and stimulates chondrocyte apoptosis through FOXO1. J Bone Miner Res (2010) 1.11
Diabetes causes the accelerated loss of cartilage during fracture repair which is reversed by insulin treatment. Bone (2008) 1.10
Lysyl oxidase propeptide inhibits smooth muscle cell signaling and proliferation. Biochem Biophys Res Commun (2007) 1.10
Activation of RAGE induces elevated O2- generation by mononuclear phagocytes in diabetes. J Leukoc Biol (2006) 1.10
Inflammation and tissue loss caused by periodontal pathogens is reduced by interleukin-1 antagonists. J Infect Dis (2002) 1.10
The transcription factor ST18 regulates proapoptotic and proinflammatory gene expression in fibroblasts. FASEB J (2008) 1.09
Diabetes aggravates periodontitis by limiting repair through enhanced inflammation. FASEB J (2011) 1.09
Diabetes enhances mRNA levels of proapoptotic genes and caspase activity, which contribute to impaired healing. Diabetes (2006) 1.08
Tissue-specific mechanisms for CCN2/CTGF persistence in fibrotic gingiva: interactions between cAMP and MAPK signaling pathways, and prostaglandin E2-EP3 receptor mediated activation of the c-JUN N-terminal kinase. J Biol Chem (2007) 1.08
FOXO1 plays an essential role in apoptosis of retinal pericytes. Mol Vis (2010) 1.04
Lysyl oxidase propeptide inhibits FGF-2-induced signaling and proliferation of osteoblasts. J Biol Chem (2010) 1.03
Abnormal cell responses and role of TNF-α in impaired diabetic wound healing. Biomed Res Int (2013) 1.02
Intracellular distribution of the lysyl oxidase propeptide in osteoblastic cells. Am J Physiol Cell Physiol (2007) 1.02
High glucose increases lysyl oxidase expression and activity in retinal endothelial cells: mechanism for compromised extracellular matrix barrier function. Diabetes (2010) 1.00
FOXO1 modulates osteoblast differentiation. Bone (2011) 0.99
Epithelial to mesenchymal transition in gingival overgrowth. Am J Pathol (2010) 0.98
Characterization of recombinant lysyl oxidase propeptide. Biochemistry (2010) 0.98
Impact of the metalloproteinase-9/tissue inhibitor of metalloproteinase-1 system on large arterial stiffness in patients with essential hypertension. Hypertens Res (2007) 0.98
Influence of diabetes on the exacerbation of an inflammatory response in cardiovascular tissue. Endocrinology (2004) 0.97
TNF-alpha in vivo stimulates apoptosis in fibroblasts through caspase-8 activation and modulates the expression of pro-apoptotic genes. J Cell Physiol (2004) 0.97
Diabetes-enhanced inflammation and apoptosis: impact on periodontal pathosis. Periodontol 2000 (2007) 0.96
Effects of OP-1 and PTH in a new experimental model for the study of metaphyseal bone healing. J Orthop Res (2007) 0.95
Etiologic factors of hyposalivation and consequences for oral health. Quintessence Int (2010) 0.95
Short- and long-term effects of IL-1 and TNF antagonists on periodontal wound healing. J Immunol (2004) 0.95
Contribution of interleukin-11 and prostaglandin(s) in lipopolysaccharide-induced bone resorption in vivo. Infect Immun (2002) 0.93
Effects of the local mechanical environment on vertebrate tissue differentiation during repair: does repair recapitulate development? J Exp Biol (2003) 0.93
Lipopolysaccharides indirectly stimulate apoptosis and global induction of apoptotic genes in fibroblasts. J Biol Chem (2003) 0.92
Chemokine expression is upregulated in chondrocytes in diabetic fracture healing. Bone (2012) 0.91
A long-term siRNA strategy regulates fibronectin overexpression and improves vascular lesions in retinas of diabetic rats. Mol Vis (2011) 0.89
Collagen advanced glycation inhibits its Discoidin Domain Receptor 2 (DDR2)-mediated induction of lysyl oxidase in osteoblasts. Bone (2013) 0.89
Regulation of collagen deposition and lysyl oxidase by tumor necrosis factor-alpha in osteoblasts. J Biol Chem (2004) 0.88
Osteogenic effects of traumatic brain injury on experimental fracture-healing. J Bone Joint Surg Am (2006) 0.88
Control of megakaryocyte expansion and bone marrow fibrosis by lysyl oxidase. J Biol Chem (2011) 0.88
Porphyromonas gingivalis strain-dependent activation of human endothelial cells. Infect Immun (2004) 0.88
The Ras signaling inhibitor LOX-PP interacts with Hsp70 and c-Raf to reduce Erk activation and transformed phenotype of breast cancer cells. Mol Cell Biol (2011) 0.88
The enduring importance of animal models in understanding periodontal disease. Virulence (2015) 0.87
Healing is delayed in oral compared to dermal excisional wounds. J Periodontol (2003) 0.87
P. gingivalis modulates keratinocytes through FOXO transcription factors. PLoS One (2013) 0.86
Recombinant lysyl oxidase propeptide protein inhibits growth and promotes apoptosis of pre-existing murine breast cancer xenografts. PLoS One (2012) 0.86
The lysyl oxidase propeptide interacts with the receptor-type protein tyrosine phosphatase kappa and inhibits β-catenin transcriptional activity in lung cancer cells. Mol Cell Biol (2011) 0.86
Diabetes and Its Effect on Bone and Fracture Healing. Curr Osteoporos Rep (2015) 0.86
Enamel matrix derivative induces connective tissue growth factor expression in human osteoblastic cells. J Periodontol (2007) 0.85
P. gingivalis and E. coli lipopolysaccharides exhibit different systemic but similar local induction of inflammatory markers. J Periodontol (2008) 0.85